Shobha Life Sciences is a leading empagliflozin manufacturer in India. This medicine is used by itself or along with other medicines to treat type- 2 diabetes. It helps in lowering the threat of heart attack, stroke, or heart failure by keeping control of sugar situations. With the increase in life conditions similar as diabetes in recent times, there's a dire need to keep a cache of these lifesaving medicines handy at all times. Pharmaceutical companies engaged in the product of similar medicines are hard- pressed to manufacture quality medicines that meet a range of quality parameters round the timepiece to meet colorful conditions all time round. Its systems and processes need to be upscaled at regular intervals, the R&D system has to be innovative, and its client engagement protocols also need to be world- class. Only also, one can hope to meet all the strict conditions of the medical institution.
At Shobha Life lores, we strive hard to meet our guests ’ conditions by delivering high- quality medicines that meet all their criteria. Although new to the business, we've set our sights on being the stylish in the business by constantly meeting all checkmarks commanded by our guests and other stakeholders while furnishing them unmatched client experience. Our leadership platoon of four directors have a concerted experience of 60 times and guide the organisation in the right direction with their sapience and intuitiveness. We also give installations for colorful preclinical trials stability studies, pharmacokinetic, pharmacodynamic, toxicological and efficacity studies. We've established a massive 6000sq. ft storehouse with ample storehouse space for immediate and unborn conditions. We run three shifts with 2MT product in every shift. Our platoon works nearly with the Chief Medical Officers for colorful medical institutions for the development of medicines and product life cycle operation for present and unborn requirements. As one of the leading empagliflozin manufacturers in India, we're concentrated not only on meeting our profit targets but also on setting marks for others to emulate.
